Berberine vs CagriSema
A side-by-side research comparison of Berberine and CagriSema across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Berberine | CagriSema |
|---|---|---|
| Full name | Berberine HCl | CagriSema (Cagrilintide + Semaglutide) |
| Category | Weight Management | Weight Management |
| Status | OTC supplement | Phase 3 Clinical Trial |
| Mechanism | Activates AMP-activated protein kinase (AMPK), the cellular energy sensor, improving insulin sensitivity, reducing hepatic glucose production, lowering LDL cholesterol, and favorably shifting the gut microbiome. | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. |
| Molecular weight | 371.81 Da | Combination product |
| Half-life | ~2.5 hours (poor systemic bioavailability) | 7 days (both components) |
| Bioavailability | Low (~5%); improved by dihydroberberine or piperine | High (SubQ) |
| Typical dose | 500 mg, 2-3x per day | Cagrilintide 2.4mg + Semaglutide 2.4mg |
| Frequency | 2-3x daily with meals | Once weekly |
| Route | Oral capsule | Subcutaneous |
Berberine reported benefits
- Improved insulin sensitivity
- Lower fasting blood glucose
- Reduced LDL and triglycerides
- AMPK activation (exercise-mimetic)
- Gut microbiome support
- Modest weight/waist reduction
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Related comparisons
Research and educational reference only. Not medical advice.